TABLE 1

Plasma growth hormone and cortisol concentrations during hyperinsulinemic, euglycemic (0–120 min) and then hypoglycemic (120–240 min) clamps before and after administration of diazoxide or placebo and later arginine hydrochloride

Time (min)Growth hormone (ng/ml)
Cortisol (μg/dl)
PlaceboDiazoxidePlaceboDiazoxide
−154.7 ± 1.55.3 ± 1.216.0 ± 1.616.4 ± 1.6
04.7 ± 1.66.1 ± 1.415.3 ± 1.615.4 ± 1.6
154.3 ± 1.35.7 ± 1.513.7 ± 1.213.4 ± 1.2
305.0 ± 1.74.4 ± 1.213.1 ± 1.312.8 ± 1.0
455.0 ± 2.13.8 ± 1.213.0 ± 1.111.7 ± 1.0
603.5 ± 1.42.8 ± 1.012.6 ± 1.111.4 ± 1.0
751.6 ± 0.52.2 ± 0.911.2 ± 1.111.4 ± 1.2
901.4 ± 0.51.8 ± 0.811.3 ± 0.99.8 ± 1.0
1050.9 ± 0.21.4 ± 0.610.9 ± 0.89.1 ± 0.9
1201.0 ± 0.21.4 ± 0.510.6 ± 0.98.4 ± 0.9
1352.5 ± 1.21.2 ± 0.49.8 ± 0.88.1 ± 0.8
1502.9 ± 1.41.6 ± 0.49.9 ± 0.88.0 ± 0.9
1653.7 ± 1.45.7 ± 1.510.8 ± 0.89.9 ± 1.2
18010.7 ± 2.516.4 ± 2.914.2 ± 1.012.9 ± 1.2
19517.6 ± 3.623.3 ± 3.916.6 ± 1.116.9 ± 1.4
21017.0 ± 2.528.5 ± 5.418.4 ± 1.118.8 ± 1.8
22519.4 ± 3.028.1 ± 4.619.5 ± 1.519.6 ± 1.9
24020.9 ± 2.925.3 ± 4.219.4 ± 1.718.9 ± 1.8
24321.4 ± 3.022.9 ± 3.117.9 ± 1.518.3 ± 1.6
24521.2 ± 3.324.4 ± 3.217.7 ± 1.617.2 ± 1.6
24722.4 ± 3.325.8 ± 3.518.5 ± 1.517.8 ± 1.7
  • Data are means ± SE. Diazoxide (6.0 mg/kg) or placebo was given orally after the 0-min sample and arginine hydrochloride (5.0 g) was injected intravenously after the 240-min sample. (Convert ng/ml to pmol/l by multiplying by 44.15, and convert μg/dl to nmol/l by multiplying by 27.59.) P = 0.0134 for placebo vs. diazoxide in growth hormone measurements; P = 0.0255 for placebo vs. diazoxide in cortisol measurements.